Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00146614 · ClinicalTrials.gov registry record · Phase 2
Tacrolimus, Sirolimus and Methotrexate as Graft Versus Host Disease Prophylaxis After Blood Stem Cell Transplantation
A Phase 2 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 105
- Enrollment target
NCT00146614 is a Phase 2 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 105 participants.
The verdict
NCT00146614, a Phase 2 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 105 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if the incidence of Graft vs. Host Disease (GVHD) after non-myeloablative transplantation can be reduced by using a combination of three immune suppressive medication; sirolimus, tacrolimus and methotrexate.
Interventions
- DRUG Sirolimus
- DRUG Tacrolimus
- DRUG Methotrexate
- PROCEDURE Stem Cell Transplantation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 105 participants |
| Start Date | 2002-07 |
| Est. Completion | 2003-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00146614
The ClinicalTrials.gov registry entry for NCT00146614 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 105 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Sirolimus is the first listed.
NCT00146614 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00146614 about?
NCT00146614 is a clinical study titled "Tacrolimus, Sirolimus and Methotrexate as Graft Versus Host Disease Prophylaxis After Blood Stem Cell Transplantation". The purpose of this study is to determine if the incidence of Graft vs. Host Disease (GVHD) after non-myeloablative transplantation can be reduced by using a combination of three immune suppressive medication; sirolimus, tacrolimus and methotrexate.
What is the current status of trial NCT00146614?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 105 participants. The study started on 2002-07. Estimated completion is 2003-04.
What interventions are being tested in trial NCT00146614?
The interventions under investigation include: Sirolimus (DRUG), Tacrolimus (DRUG), Methotrexate (DRUG), Stem Cell Transplantation (PROCEDURE).
Who is sponsoring clinical trial NCT00146614?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.